Blog
Transforming growth factor beta (TGF-β) activity in immuno-oncology studies
Besides its well-known roles in cancer, fibrosis, and cardiovascular disease, TGF-β has gained increasing importance in the treatment and indications of immune and autoimmune diseases in recent years. This publication (PMID: 32178817) discusses the significance of quantifying the activity of Transforming Growth Factor Beta (TGF-β) in various biological contexts, particularly in immuno-oncology studies. Measuring TGF-β activity presents several challenges due to its complex nature and the various forms it can take. To address this, several methodologies are available to accurately assess TGF-β activity, including: o Western Blotting (WB): This method is considered the primary approach for analyzing cellular signaling pathways by detecting specific proteins. o Flow Cytometry (FC): This technique allows for the quantitative analysis of TGF-β presence on cell surfaces or within cells. However, it requires careful handling to avoid inducing artificial results. o Luminex and ELISA: These standard methods are commonly used to measure TGF-β levels, although they
P144 a Transforming Growth Factor Beta Inhibitor Peptide, Generates Antifibrogenic Effects in a Radiotherapy Induced Fibrosis Model
Our focus is on developing a product with significant potential for treating radiation-induced fibrosis. Disitertide has shown considerable promise in preclinical studies, effectively inhibiting TGF-β signaling, a key driver of
A synthetic peptide from transforming growth factor β type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury
Our focus lies in developing a peptide with scientifically validated potential to transform the treatment of fibrosis and related conditions. This scientific foundation underscores our dedication to translating cutting-edge discoveries
P144 a Transforming Growth Factor Beta Inhibitor Peptide, Generates Antifibrogenic Effects in a Radiotherapy Induced Fibrosis Model
Our focus is on developing a product with significant potential for treating radiation-induced fibrosis. Disitertide has shown considerable promise in preclinical studies, effectively inhibiting TGF-β signaling, a key driver of
A synthetic peptide from transforming growth factor β type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury
Our focus lies in developing a peptide with scientifically validated potential to transform the treatment of fibrosis and related conditions. This scientific foundation underscores our dedication to translating cutting-edge discoveries
